Department of Pharmaceuticals continues with special campaign for disposal of pending matters

Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines

Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API

Alembic Pharmaceuticals receives USFDA final approval for Albendazole Tablets USP, 200 mg

Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India

Effective, holistic, science-backed targeted solutions for symptomatic treatment

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24

Jagsonpal Pharmaceuticals Q1 FY25 revenues at Rs. 61.4 Crores, 41% growth over Q4 FY24

The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.

Fredun Pharmaceuticals Q1 FY25 PAT drops QoQ to Rs. 4.12 Cr

Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024

Briefs: Indoco Remedies and Alembic Pharmaceuticals

Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe